Nateglinide

Drugs

Volumn 60, Issue 3, 2000, Pages 607-615

  Dunn, C J ^a   Faulds, D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; TOLBUTAMIDE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RAT;

ANIMALIA;

EID: 0033781630     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060030-00007     Document Type: Article

References (30)

1. New insulin secretagogues for the treatment of type 2 diabetes
2. 2+ influx
3. Tissue selectivity of nateglinide: Study on cardiovascular and β-cell K(ATP) channels
4. Pancreatic β-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide
5. Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas
6. + concentrations
7. 2+-evoked, K(ATP)-channel independent, secretion in rat pancreatic α- and β-cells
8. 3H]glibenclamide
9. Effect of antidiabetic agent, nateglinide, on K(ATP) channel in β-cells: Comparison to glyburide and repaglinide
10. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells
11. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166)
12. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: Comparison with voglibose and glibenclamide
13. AY-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas
14. Stimulation of insulin and somatostatin release by two meglitinide analogs
15. Effects of N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) on insulin and glucagon secretion in isolated perfused rat pancreas
16. The new oral hypoglycaemic agent A4166 enhances 1st phase insulin secretion in diabetic man
17. Comparison of mealtime glucose regulation by nateglinide and repaglinide in healthy subjects
18. Pharmacodynamics and dose response of nateglinide in type 2 diabetics
19. Nateglinide, but not glyburide, selectively enhances early insulin release and more effectively controls post-meal glucose excursions with less total insulin exposure
20. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose spikes in type 2 diabetes
21. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin
22. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus
23. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic actions of the agent nateglinide in healthy subjects
24. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis
25. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166
26. Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent
27. Nateglinide, a new mealtime glucose regulator: Lack of pharmacokinetic interaction with digoxin in healthy volunteers
28. Nateglinide improves glycemic control alone and in combination with troglitazone in patients with type 2 diabetes
29. Nateglinide added to metformin offers safe and effective treatment for type 2 diabetes
30. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia